Liggett S B
Departments of Medicine and Molecular Genetics, University of Cincinnati College of Medicine, Ohio, USA.
J Allergy Clin Immunol. 2000 Feb;105(2 Pt 2):S487-92. doi: 10.1016/s0091-6749(00)90048-4.
The beta(2)-adrenergic receptor (beta(2)AR) is the molecular target for beta-agonists used in the treatment of asthma. In the human population, 4 polymorphisms of the beta(2)AR coding block have been found, 3 of which result in receptors that have different properties compared with wild-type. To date, clinical studies suggest that these beta(2)AR polymorphisms may alter asthmatic phenotype and the response to beta-agonist therapy, making these variants the first of undoubtedly several genetic loci that will ultimately be found that will provide for individualized therapy in asthma.
β₂肾上腺素能受体(β₂AR)是用于治疗哮喘的β激动剂的分子靶点。在人类群体中,已发现β₂AR编码区有4种多态性,其中3种导致产生的受体与野生型相比具有不同特性。迄今为止,临床研究表明,这些β₂AR多态性可能会改变哮喘表型以及对β激动剂治疗的反应,这使得这些变异成为首批无疑将最终被发现的、可为哮喘个体化治疗提供依据的若干基因位点中的第一个。